Log in to search using one of your social media accounts:


Prostatectomy vs Radiotherapy: 15-Year Functional Outcomes Are the Same

Fifteen years after treatment for localized prostate cancer, men who underwent radical prostatectomy reported no differences in urinary, bowel, or sexual function compared with men who underwent external-beam...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news

Related Links:

ConclusionsThe incidence of MUIP, hospital admissions and open surgical procedures following radiation is reassuringly low. The second malignancy rates are also low and similar to the rates in patients treated with a prostatectomy.
Source: Asia-Pacific Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
To compare toxicity rates in patients with localized prostate cancer treated with standard fractionated external beam radiotherapy (EBRT) with or without an additional integrated boost to the macroscopically visible tumour.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original article Source Type: research
ObjectivesTo determine the predictors of testosterone recovery after termination of androgen deprivation therapy in high/intermediate‐risk prostate cancer patients receiving external beam radiation therapy with neoadjuvant and adjuvant androgen deprivation therapy. MethodsA total of 82 patients who underwent external beam radiation therapy with androgen deprivation therapy for prostate cancer were retrospectively analyzed. Serum testosterone levels after androgen deprivation therapy terminations were studied. Cox proportional hazard models and the Kaplan–Meier method were used for statistical analysis. ResultsMedia...
Source: International Journal of Urology - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
CONCLUSIONS: In intermediate- and high-risk prostate cancer patients, focal dose escalation integrated with standard EBRT did not result in an increase in GU and GI toxicity when compared to the standard treatment up to two years after treatment. This suggests that the described focal dose escalation technique is safe and feasible. PMID: 29336835 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Abstract ObjectiveTo evaluate the cancer control outcomes and long‐term treatment‐related morbidity of brachytherapy as well as combination brachytherapy and EBRT in patients with intermediate‐risk prostate cancer. Materials and MethodsA retrospective review was conducted in a prospectively collected database of patients with intermediate‐risk prostate cancer who were treated either with brachytherapy or brachytherapy and EBRT, with or without ADT, from 1990‐2014. Urinary and erectile dysfunction symptoms are measured using the International Prostate Symptom Score (IPSS) and the Mount Sinai erectile function scal...
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Abstract Though previous major abdominal surgery and pelvic irradiation may be a significant drawback of subsequent laparoscopic procedure, technological advances such as better visualization and more controlled finer movementsof robotic arms allowing better dissection in robotic-assisted laparoscopic surgery may reduce some of these challenges. However, limited data are available on the effect and safety of robotic surgery in these patients. The aim of this case report is to present efficacy and safety of robot assisted radical prostatectomy in a patient who has rectal and concurrent prostate cancer with the hist...
Source: Urology Journal - Category: Urology & Nephrology Authors: Tags: Urol J Source Type: research
Background/Aim: Prostate cancer can be treated with radical prostatectomy (RP), external-beam radiotherapy (EBRT), or brachytherapy (BT). These modalities have similar cancer-related outcomes. We used an innovative method to analyze the cost of such treatment. Materials and Methods: We queried our Institution's Insurance Division [University of Pittsburgh Medical Center (UPMC) Health Plan] beneficiaries from 2003-2008, who were diagnosed with prostate cancer and also queried the UPMC tumor registry for all patients with prostate cancer treated at our Institution. In a de-identified manner, data from the Health Plan and Tum...
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
Abstract IntroductionThe aim of this study was to evaluate the use of high‐dose‐rate brachytherapy (HDR‐BT) boost with definitive external beam radiotherapy (EBRT) in prostate cancer (CaP) management. MethodsThe study population comprised men with intermediate‐high risk CaP captured in the population‐based Prostate Cancer Outcome Registry Victoria (PCOR‐Vic), treated with EBRT from January 2010 to December 2015. The primary outcome is the proportion of men who received HDR‐BT boost. Multivariate logistic regressions were used to evaluate the effect of patient‐, tumour‐ and treatment‐factors on the likel...
Source: Australasian Radiology - Category: Radiology Authors: Tags: Radiation Oncology —Original Article Source Type: research
Abstract The aim of the present study was to determine whether oncologic outcomes and adverse events associated with active on/off intermittent antiandrogen monotherapy (daily bicalutamide, 50 mg per day) are comparable with those of standard external beam radiation therapy (EBRT) or combined androgen blockade (CAB) therapy in prostate cancers with positive surgical margins after radical prostatectomy. Two hundred twenty-three patients with positive surgical margins post-radical prostatectomy who underwent active surveillance (AS, n = 32), EBRT without hormone therapy (n = 55), intermittent antiandrogen monotherap...
Source: Asian Journal of Andrology - Category: Urology & Nephrology Authors: Tags: Asian J Androl Source Type: research
Brachytherapy (BT) monotherapy is a well-established treatment modality for favorable intermediate risk (FIR) prostate cancer. However, patients with unfavorable intermediate risk (UIR) disease are often recommended trimodality therapy involving BT, androgen deprivation therapy (ADT), and external beam radiation therapy (EBRT). We sought to investigate the relative benefit of supplemental therapies (ADT and/or EBRT) for FIR and UIR prostate cancer in a large dataset.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original article Source Type: research
More News: Cancer | Cancer & Oncology | External Beam Therapy | Prostate Cancer